Compare DraftKings Inc (DKNG) vs TG Therapeutics Inc (TGTX) Price & Performance

DraftKings (DKNG) trades at $25.79, up 6.24% on the day, with a bullish technical signal and strong analyst consensus. Revenue grew to $6.05 billion in 2025, though recent quarters show earnings misses. The company is expanding into prediction markets, with CEO Jason Robins highlighting rapid growth ahead of the NFL season (Bloomberg Technology, 2026-08-07).

The outlook is mixed: strong revenue growth and positive cash flow from operations contrast with high valuation multiples and recent profitability challenges. Key risks include competition from prediction markets and promotional costs pressuring margins. The consensus price target of $34.00 suggests upside potential if execution improves.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.